695 results about "Whole blood sample" patented technology

A method for tutoring a user in use of a kit for determining an analyte (such as glucose) in a bodily fluid sample (for example a whole blood sample) includes activating an analytical meter of the kit, with the analytical meter including a display-based tutorial module. In addition, the display-based tutorial module includes a user interface with a visual display, a memory unit storing a tutorial, and a microprocessor unit configured for controlling and coordinating the user interface and the memory unit. Moreover, the tutorial stored in the memory unit has chapters with each of the chapters containing one or more tutorial images depicting use of the kit. In addition, the user interface, microprocessor unit and memory unit are operatively linked and configured for event-driven chapter-based display of the tutorial images to a user on the visual display. The method also includes tutoring the user on use of the kit by displaying the tutorial images in an event-driven chapter-based manner.

A method for separating, or removing, particulate material, e.g., blood cells, from a sample of fluid, e.g., whole blood of a patient, in which the particulate material is suspended. In the case of separating blood cells from blood plasma or blood serum, the resulting samples of blood plasma or blood serum can be used for in vitro diagnostic applications. In normal practice, a whole blood sample of a patient are provided and then introduced into an apparatus that contains a flow channel. An acoustic field, which contains acoustic standing waves from external ultrasonic transducers, is located within the flow channel. Laminar flow is maintained in the flow channel. Blood cells and platelets are separated from blood plasma or blood serum at the end of the flow channel and collected. The method described herein allows fluid components to differentially migrate to areas of preferred acoustic interaction. The parameters that affect separation of particles are size, density, compressibility of the particles, and the fluid surrounding the particles.

A test strip for the determination of an analyte, such as glucose, in a body fluid sample (for example, a whole blood sample) includes a substrate with a working surface for receiving the body fluid sample and a reverse surface that is in opposition to the working surface. The test strip also includes a permutative grey scale calibration pattern disposed on either of the working and reverse surfaces with the permutative grey scale calibration pattern including more than one grey scale region. Moreover, the scale regions of the test strip define a grey scale permutation that uniquely corresponds to a calibration code of the test strip.

A kit for determining an analyte (e.g., glucose) in a bodily fluid sample (for example a whole blood sample) includes a meter and analytical test strip(s). In addition, the meter includes a display-based tutorial module with a memory unit, a microprocessor unit and a user interface that includes a visual display. The memory unit is configured for storing a tutorial, while the microprocessor unit is configured for controlling and coordinating the user interface and the memory unit. In addition, the tutorial stored in the memory unit has chapters, with each of the chapters containing one or more tutorial images depicting use of the kit. Moreover, the analytical test strip is configured for the application of a bodily fluid sample thereon and for insertion in the meter for subsequent determination of the analyte. Furthermore, the user interface, microprocessor unit and memory unit are operatively linked and configured for event-driven chapter-based display of the tutorial images to a user on the visual display.

A method and apparatus for identifying one or more target constituents (e.g., white blood cells) within a biological sample is provided. The method includes the steps of: a) adding at least one colorant to the sample; b) disposing the sample into a chamber defined by at least one transparent panel; c) creating at least one image of the sample quiescently residing within the chamber; d) identifying target constituents within the sample image; e) quantitatively analyzing at least some of the identified target constituents within the image relative to one or more predetermined quantitatively determinable features; and f) identifying at least one type of target constituent within the identified target constituents using the quantitatively determinable features.

The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 μg/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.

An apparatus is disclosed that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

A method for enumerating white blood cells and nucleated red blood cells. The method comprises the steps of:

• • (b) providing a lysed sample of whole blood;
  • (b) introducing the lysed sample to a light-scattering multi-angle depolarizing flow cytometer;
  • (c) removing depolarizing interference, e.g., lipid droplets and other measured particles;
  • (d) differentiating nucleated red blood cells and noise from white blood cells in the absence of depolarizing interference;
  • (e) differentiating nucleated red blood cells from noise in the absence of depolarizing interference and white blood cells; and
  • (f) differentiating possible platelet clumps.

The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads; and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

A method of determining glycated hemoglobin is provided, by which a ratio of the glycated hemoglobin in a sample can be determined accurately and easily. The ratio of glycated hemoglobin can be determined by degrading a glycated hemoglobin in a whole blood sample selectively with a protease to give a glycated hemoglobin degradation product`; causing a redox reaction between a glycation site of the glycated hemoglobin degradation product and a fructosyl amino acid oxidoreductase; and determining this redox reaction. Further, as shown in FIG. 1, in a whole blood sample, there is a correlation between the ratio of the glycated hemoglobin determined by this method and an HbA1c concentration. Thus, without determining the glycated alpha-amino group as a characteristic structure of HbA1c, an amount of HbA1c can be determined accurately and easily from the determined ratio of the glycated hemoglobin.

The present invention is a flow cytometry-based hematology system useful in the analysis of biological samples, particularly whole blood or blood-derived samples. The system is capable of determining at least a complete blood count (CBC), a five-part white blood cell differential, and a reticulocyte count from a whole blood sample. The system preferably uses a laser diode that emits a thin beam to illuminate cells in a flow cell and a lensless optical detection system to measure one or more of axial light loss, low-angle forward scattered light, high-angle forward scattered light, right angle scattered light, and time-of-flight measurements produced by the cells. The lensless optical detection system contains no optical components, other than photoreactive elements, and does not include any moving parts. Finally, the system uses a unique system of consumable reagent tubes that act as reaction chambers, mixing chambers, and waste chambers for the blood sample analyses. The consumable tubes incorporate reference particles, which act as internal standards to ensure that the dilutions made during processing of the samples have been carried out correctly, and to ensure that the instrument is working properly. The present invention also relates to methods for using the system.

The invention discloses a method for detecting fluorescence resonance energy transfer by using a water-soluble upconversion fluorescence nanomaterial as a fluorescence donor and using a carbon nanomaterial as a fluorescence receptor. The method comprises the following specific steps: (1) preparing the water-soluble upconversion fluorescence nanomaterial and performing surface marker to obtain a fluorescence donor solution; (2) preparing the carbon nanomaterial to obtain a fluorescence receptor solution; (3) mixing the fluorescence donor solution and the fluorescence receptor solution for incubation and measuring the fluorescence intensity to obtain a fluorescence quenching curve; (4) mixing certain-concentration fluorescence donor solution and certain-concentration fluorescence receptor solution for incubation, adding a target object with different concentrations for continuous incubation, measuring the fluorescence intensity and drawing a standard curve; (5) calculating the concentration of the target object in an actual sample according to the standard curve. According to the method, interference of the background fluorescence of a biological sample can be avoided, detection to serum or the target object in a whole blood sample can be directly realized, the washing and separation processes are not needed, the detection speed is high, and the cost is low.

A device, system and method for photometric detection of coagulation in whole blood. The present invention is easy to implement and operate. Furthermore, the present invention has the advantage of being considered to fulfill the desired standard of using photometry for measuring blood coagulation. Also, a photometric coagulation test device for whole blood specimens according to the present invention provides medical accuracy to the home user and, at the same time, is simple to construct. The present invention is also useful for detecting and determining blood agglutination, for example as the results of a serological reaction with an antibody.

The invention provides a method for detecting trace elements in human body whole blood through an inductively coupled plasma mass spectrometry method and belongs to the technical field of biotechnical detection. The method comprises the following steps: (1) pre-treating a whole blood sample; (2) detecting a mixed element standard solution and a to-be-detected sample solution by an inductively coupled plasma mass spectrometer; and (3) performing quantitative analysis on a detection result and calculating the content of to-be-detected elements in the human body whole blood sample. The method provided by the invention can be used for simultaneously detecting the content of trace elements, such as magnesium, manganese, calcium, iron, copper, zinc and lead, in the human body whole blood; the sample dosage is less; the pretreatment is simple; the cost is low; the whole detection process is short in time and high in efficiency; the detection sensitivity and precision andthe detection stability are high.

A device for separating plasma from whole blood is provided having an evacuated primary collection chamber capable of fluid communication through a porous filter to an evacuated secondary collection chamber. An agglutinating agent is provided within the primary collection chamber so as to aggregate blood cells within a whole blood sample. The porous filter has a pore size which is small enough to capture the aggregated blood cells therein, yet large enough to permit plasma to transfer therethrough under pressures associated with conventional evacuated blood collection tubes. The primary and secondary collection chambers may be provided in separate containers or tubes, with transfer occurring therebetween through a transfer device including the porous filter therein.

A multilayer test strip and method of using the test strip for determining concentration of HDL cholesterol in a whole blood sample. The inventive test strip includes a two-stage blood separation mechanism, including a first glass fiber matrix which separates most of the blood cells and an adjacent, second matrix preferably also containing glass fibers that separates the remainder of the blood cells. The second layer also precipates and retains non-HDL cholesterol, thereby providing plasma that is substantially free of red blood cells and substantially free of non-HDL cholesterol to a reaction layer. Precipitation and retention on non-HDLs takes place by a vertical or dead-end filtration in a single layer. The reaction layer produces a color, the intensity of which is proportional to the concentration of HDL cholesterol in the blood sample which is applied to the test strip. Advantageously, the inventive test strip is a vertical flow device, which can be made more compact and operates more efficiently than a lateral flow device.

Disclosed in one aspect is a method for performing a complete blood count (CBC) on a sample of whole blood by metering a predetermined amount of the whole blood and mixing it with a predetermined amount of diluent and stain and transferring a portion thereof to an imaging chamber of fixed dimensions and utilizing an automated microscope with digital camera and cell counting and recognition software to count every white blood cell and red blood corpuscle and platelet in the sample diluent/stain mixture to determine the number of red cells, white cells, and platelets per unit volume, and analyzing the white cells with cell recognition software to classify them.

A GMR based sensor device (100) for sensing first particles (504, 505) e.g. magnetic beads for immuno assay of a sample comprising the first particles (504, 505) and second particles (503) e.g. red blood cells, the sensor device (100) comprising a detection unit (11, 12) adapted to detect a signal which depends on a quantity of the first particles (504, 505) and which depends on a quantity of the second particles (503)″ based on a measurement performed with the sample comprising the first particles (504, 505) and the second particles (503), an estimation unit (30) for estimating information indicative of the quantity of the second particles (503) e.g. haematocrit based on an impedance measurement, and a determining unit (20) adapted for determining the quantity of the first particles (504, 505) based on the detected signal under consideration of the estimated information. The advantage of this arrangement is that whole blood samples may be used.

A method and apparatus for analyzing white blood cells (WBCs) within a whole blood sample quiescently residing within a chamber is provided. The chamber is defined by at least one transparent panel, and the whole blood sample includes at least one colorant operable to differentially identify at least one WBC type from another WBC type within the sample. The method includes the steps of: a) creating at least one image of the sample quiescently residing within the chamber; b) identifying portions of the sample image, with each portion representing a single WBC; c) compressing the sample image portions using a first compression algorithm; and d) one of compressing a remainder of the sample image not included in the portions using a second compression algorithm, or discarding the remainder.